Christian Ruzanski

Company: Novo Nordisk

Job title: Principal Scientist

Seminars:

An In Vitro Diagnostic Test for Dose Maintenance Setting in Patients Treated with Concizumab 2:00 pm

Concizumab is an anti TFPI monoclonal antibody intended for all haemophilia A and B types Treatment with concizumab require dose maintenance setting based on concizumab exposure levels 4 weeks after treatment initiation using an IVD A ConcizuTrace ELISA test access solution provides a complete service portal for CDx test ordering and CDx test result provisionRead more

day: Day 1 - Track B (1)